Abstract 120P
Background
Cetuximab (Cet) plus chemotherapy (CT) has been approved as preferred first-line (1L) treatment for left-sided (LS) metastatic colorectal cancer (mCRC) with wild-type (wt) RAS/BRAF gene. However, it remains uncertain whether Cet is beneficial as maintenance therapy after 1L treatment. This study aimed to investigate the clinical outcomes for maintenance therapy in pts with LS RAS/BRAF wt mCRC who responded to 1L Cet plus CT.
Methods
We performed a retrospective review of pts with LS RAS/BRAF wt mCRC who had disease controlled (CR, PR or SD) after 6 cycles of Cet based induction therapy from JAN 2018 to JUN 2022 at HuNan Cancer Hospital. The 1L regimen consists of Cet plus mFOLFOX6 or FOLFIRI, based on pts selection, followed by maintenance therapy with Cetuximab with or without chemotherapy (cohort A) or chemotherapy alone (cohort B). Death data were obtained from the government's death registry. Kaplan-Meier methods were employed to describe overall survival (OS) and progression-free survival (PFS).
Results
A total of 125 pts were included in this study, with 72 (57.6%) in cohort A and 53 (42.4%) in cohort B. The median age was 58 years (range: 23-76), and 86 (68.8%) were male. The most common site of metastasis was the liver (90 patients, 72.0%). During a median follow-up of 32.6 m, the median OS from the start of 1L therapy was significantly longer in cohort A (46.4 m, 95% CI 40.1-NA) than in cohort B (31.1 m, 95% CI 27.6-38.0; p < 0.0001). Similarly, cohort A (14.2 m, 95% CI 12.4-17.0) had a significantly longer median PFS than cohort B (11.0 m, 95% CI 9.6-11.7; p=0.021). The Cox proportional hazards model, after adjusting for age, sex, primary tumor location, metastatic site, and whether the primary tumor and metastases were resected or not, showed that compared with cohort B, cohort A was associated with a statistically significant longer OS (HR 0.43, 95% CI 0.25-0.73) and a longer PFS, although the difference was not statistically significant (HR 0.70, 95% CI 0.44-1.12).
Conclusions
Maintenance therapy with Cet can significantly improve OS in pts with LS RAS/BRAF wt mCRC and lead to a clinically meaningful improvement in PFS, although the statistical difference was not reached.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
485P - LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers
Presenter: Sai-Hong Ou
Session: Poster Display
Resources:
Abstract
486P - Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong’s healthcare system
Presenter: Herbert Ho Fung Loong
Session: Poster Display
Resources:
Abstract
487P - Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patients
Presenter: Jian Wei Tan
Session: Poster Display
Resources:
Abstract
488P - Pulmonary ground glass opacity lesions: Immune ecosystem and its clinical relevances of early-stage lung adenocarcinoma
Presenter: Shensi Shen
Session: Poster Display
Resources:
Abstract
489TiP - BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
Presenter: Wentao Yu
Session: Poster Display
Resources:
Abstract
491P - Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
Presenter: Ziheng Wu
Session: Poster Display
Resources:
Abstract
492P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display
Resources:
Abstract
493P - The prognostic value of 4L lymph node dissection in left-sided operable non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Lei Peng
Session: Poster Display
Resources:
Abstract
495P - Intrinsic STING of CD8+T cells regulates self-metabolic reprogramming and exerts anti-tumor effects
Presenter: Qiuli Xu
Session: Poster Display
Resources:
Abstract
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract